FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, specifically to compositions for inducing angiogenesis in tissues, and can be used in medicine. The method provides transforming the strain E. coli TOP10 by the pCMV-VEGF165 plasmid, culturing the strain in an environment acceptable for the biomass collection followed by separating the superhelical pCMV-VEGF165 plasmid that is followed by the pCMV-VEGF165 plasmid lyophilisation, which is conducted in the necessary presence in the lyophilised solution of a cryoprotectant, a pH stabiliser, an antioxidant and other substances enabling producing normal saline for injections with the pure plasmid concentration of 0.1 to 10 mg/ml and pH 7.0 to 9.0 and providing t the superhelical form of the pCMV-VEGF165 plasmid storage retention. The method of treating an individual's tissue and/or organ ischemia consists in administering an effective amount of the prepared pharmaceutical composition intramuscularly into the individual.
EFFECT: invention enables preparing the therapeutically applicable pharmaceutical composition of the pCMV-VEGF165 plasmid DNA with preserving properties of the main substance at long-term storage at +2-+8°C.
3 cl, 2 dwg, 4 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
DRUG COMBINATION FOR GENE-IMMUNE THERAPY | 2022 |
|
RU2792683C1 |
CODON-OPTIMISED SEQUENCES AND PHARMACEUTICAL COMPOSITION FOR RECOVERY OF BLOOD VESSELS | 2014 |
|
RU2557385C1 |
CODON-OPTIMISED CDNA CODING HUMAN DYSFERLIN, GENETICALLY ENGINEERED CONSTRUCT, RECOMBINANT ADENOVIRUS AND PHARMACEUTICAL COMPOSITION FOR TREATING DYSFERLINOPATHIES | 2012 |
|
RU2527073C2 |
GENETIC ENGINEERING STRUCTURE FOR ANGIOGENESIS STIMULATION | 2019 |
|
RU2737487C1 |
OPTIMIZED NUCLEOTIDE SEQUENCE AND PHARMACEUTICAL COMPOSITIONS BASED THEREON WITH SUSTAINED VEGF TRANSGENE EXPRESSION | 2015 |
|
RU2612497C2 |
SOLUTION FOR INJECTION, RECOMBINANT PLASMID DNA pSX50 ENCODING SYNTHESIS OF HUMAN RECOMBINANT ALPHA-2b INTERFERON, STRAIN Escherichia coli SX50 AS INDUSTRIAL STRAIN-PRODUCER OF HUMAN RECOMBINANT ALPHA-2b INTERFERON AND METHOD FOR INDUSTRIAL PREPARING INTERFERON ALPHA-2b | 2006 |
|
RU2319502C1 |
LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR NAKED DNA GENE THERAPY | 2019 |
|
RU2795471C2 |
PLASMINOGEN UROKINASE TYPE MODIFIED ACTIVATOR, DNA SEQUENCE, RECOMBINANT PLASMID, STRAIN-PRODUCER, METHOD FOR PREPARING PLASMINOGEN UROKINASE TYPE MODIFIED ACTIVATOR AND PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC EFFECT | 2001 |
|
RU2247777C2 |
RECOMBINANT PLASMID pESAT6-CFP10-DBD, RECOMBINANT STRAIN Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], METHOD FOR PREPARING, IMMOBILISING, CONCENTRATING AND PURIFYING RECOMBINANT PROTEIN ESAT6-CFP10-DBD ON DEXTRAN, RECOMBINANT PROTEIN ESAT6-CFP10-DBD AND IMMUNOGENIC COMPOSITION CONTAINING PROTEIN ESAT6-CFP10-DBD | 2013 |
|
RU2539026C1 |
RECOMBINANT PLASMID DNA ENCODING SYNTHESIS, METHOD FOR PREPARING AND PREPARATION OF HUMAN RECOMBINANT GAMMA-INTERFERON | 2002 |
|
RU2214832C1 |
Authors
Dates
2015-02-20—Published
2012-08-31—Filed